VIRxSYS Corporation Licence

Oxford Biomedica PLC
10 March 2006






FOR IMMEDIATE RELEASE                                           10 MARCH 2006


                              Oxford BioMedica Plc

OXFORD BIOMEDICA LICENSES ITS GENE DELIVERY TECHNOLOGY TO VIRXSYS CORPORATION

Oxford, UK - 10 March 2006: Oxford BioMedica Plc (LSE: OXB), the leading gene
therapy company and VIRxSYS Corporation (Gaithersburg, Maryland USA) today
announce a licence agreement for Oxford BioMedica's VSV-G viral envelope
technology for gene delivery. The agreement provides VIRxSYS with rights to
utilise this technology in the production process of VIRxSYS's anti-HIV/AIDS
product VRX496 which is currently in Phase II trials. Under the agreement,
Oxford BioMedica receives an upfront licence fee and annual maintenance
payments. In addition, Oxford BioMedica will receive payments on the achievement
of clinical and regulatory milestones by VIRxSYS and product royalties. Further
financial details were not disclosed.



Oxford BioMedica's CEO, Professor Alan Kingsman, said: 'We are delighted to
welcome VIRxSYS to the growing list of Oxford BioMedica's technology licensees.
This agreement further underlines the breadth and strength of our proprietary
gene delivery technologies.'



                                        -Ends-




For further information, please contact:
Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive                Tel: [phone]
City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan   Tel: [phone]
Communications
Scientific/Trade Press Enquiries:
Sue Charles/ Katja Stout/ Ashley Lilly                  Tel: [phone]
Northbank Communications


Notes to editors



1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.



Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes an immunotherapy and a gene therapy in multiple Phase II trials, and a
preclinical targeted antibody therapy in collaboration with Wyeth. In
neurotherapy, the Company's lead product is a gene therapy for Parkinson's
disease, which is expected to enter clinical trials in 2006, and four further
preclinical candidates. The Company is underpinned by over 80 patent families,
which represent one of the broadest patent estates in the field.



The Company has a staff of approximately 70 split between its main facilities in
Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations with Wyeth, Intervet,
Sigma-Aldrich, Viragen, MolMed and Kiadis; and has licensed technology to a
number of companies including Merck & Co, Biogen Idec and Pfizer.



Further information is available at www.oxfordbiomedica.co.uk



2. VIRxSYS Corporation

VIRxSYS' mission is to become the leading technology company for delivering
biologic and gene therapies into cells. The Company has created a lentiviral
gene delivery technology which is the critical link to delivering genetic
medicines for the treatment of a broad range of life-threatening diseases such
as HIV/AIDS and cancer.

The Company expects that its genetic medicines will provide dramatically
improved patient outcomes, including disease remission and possibly permanent
cures. While VIRxSYS' initial focus is on cellular therapies for HIV/AIDS and
various cancers, the Company's numerous collaborations include work towards
vaccines for those terrible diseases. Eventually, the Company intends to apply
the Company's technology to other diseases as well as possibly to countering
bioterrorism and functional genomics.

Delivery of the Company's products will initially use ex-vivo cell processing,
followed in time by in-vivo injectables and other techniques for the most
effective delivery to the targeted cells and diseases. VIRxSYS plans to select
strategic partners to significantly advance the Company's research and
development and manufacturing scalability. In addition, such partners may also
be used for sales, marketing and delivery of the Company's products.



Further information is available at http://www.VIRxSYS.com






                      This information is provided by RNS
            The company news service from the London Stock Exchange     
AGRFGGMFVGKGVZG